Does Cytoreductive Therapy Reduce the Risk of Blood Clots in MPNs?
Topic Areas:
Myeloproliferative Neoplasms
View next
Published on June 20, 2016
Patient Power community member, Joan, asks, "What is cytoreductive therapy, and does it reduce the risk of blood clots?". Dr. Mark Heaney of Columbia University Medical Center answers this question by defining cytoreduction and by providing background information related to clinical trial results. Listen as Dr. Heaney discusses the role of cytoreductive therapy in the treatment of essential thrombocythemia (ET).
The Ask the Expert series is sponsored through an educational grant to the Patient Empowerment Network from Incyte Corporation.
